GW0742: Cardarine Sans Cancer (maybe?)
GW0742 is a PPAR-delta agonist compound being investigated by GSK. If PPAR-delta agonist sounds familiar, that's because this is in the same category of compound as Cardarine, and potentially has a similar use. Related articles include
Also search the /r/PEDsR subreddit for a full list (we've covered it many times!).
There are no human trials to work with, and no animal trials looking at body composition / endurance (yet), so let's look at the leading indicators.
- Increases Insulin Sensitivity (in rats) - In diabetic rats fed a high fructose diet, the group given GW0742 had lower blood sugar than control, and insulin sensitivity was increased. From what we knew of Cardarine and PPAR-d agonists, this is an expected result.
- Improves Expression of Type 2 Collagen (in combination with other common osteoperosis treatment methods) - GW0742 greatly enhanced mesenchymal stem cells chondrogenesis and the expression of type II collagen and glycosaminoglycan in hBM-MSC-derived chondrocytes... (and if you understand any of that I'll be impressed. I sure don't.). GW0742 also indirectly reduced cartilage wear and tear.
- Promotes reverse cholesterol transport - Mice treated with 10mg/kg per day for 2 weeks increased reverse cholesterol transport. What this means is that it's moving cholesterol back to the liver, and eventually feces (poop), which should lower total cholesterol.
- Reduces Inflammation in Gut - Under a microscope, inflammation is reduced in the affected area by about 50-80% (my estimate from the photos). There's a bunch of data I am not familiar with to make further claims.
- Limits Right Heart Hypertrophy - In subjects with pulmonary hypertension, GW0742 relaxes in systemic and pulmonary vessels, and the dilator effects are independent of the PPAR-d receptor activation. Or in other words, it is cardiac protective which is in addition to any PPAR-d activation benefit. In this area it had a very similar effect to Cardarine. Rats took 30mg/kg for 3 weeks, and significantly reduced systolic pressure (researchers claim, I looked through the data and I couldn't find it).
- Enhances Lipid Metabolism - One of the reported benefits of Cardarine is the improvement in lipids. This seems to be the case for PPAR-d agonists in general. This was re-established for GW0742 in rats treated with 5mg/kg for 7 days. Fatty acid oxidation & TCA cycle genes were upregulated... transcription were increased significantly (>100%).
Words of Caution
Keep in mind that Cardarine was ran at a relative high Human Effective Dose for over a year in rats. These type of long term studies will be essential to predict risk in humans, as the longest study I could find (3 weeks) is not conclusive.
It's likely that all PPAR-d agonists will improve cardiac performance and key health markers. However, for this compount, the side effects are not well known at all.